CA2785253A1 - Calcipotriol monohydrate nanocrystals - Google Patents

Calcipotriol monohydrate nanocrystals Download PDF

Info

Publication number
CA2785253A1
CA2785253A1 CA2785253A CA2785253A CA2785253A1 CA 2785253 A1 CA2785253 A1 CA 2785253A1 CA 2785253 A CA2785253 A CA 2785253A CA 2785253 A CA2785253 A CA 2785253A CA 2785253 A1 CA2785253 A1 CA 2785253A1
Authority
CA
Canada
Prior art keywords
poloxamer
polysorbate
calcipotriol monohydrate
nanocrystals
calcipotriol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2785253A
Other languages
English (en)
French (fr)
Inventor
Karsten Petersson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Leo Pharma AS
Original Assignee
Leo Pharma AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leo Pharma AS filed Critical Leo Pharma AS
Publication of CA2785253A1 publication Critical patent/CA2785253A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/592—9,10-Secoergostane derivatives, e.g. ergocalciferol, i.e. vitamin D2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C35/00—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a ring other than a six-membered aromatic ring
    • C07C35/21—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a ring other than a six-membered aromatic ring polycyclic, at least one hydroxy group bound to a non-condensed ring
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA2785253A 2009-12-22 2010-12-22 Calcipotriol monohydrate nanocrystals Abandoned CA2785253A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DKPCT/DK2009/000267 2009-12-22
DK2009000267 2009-12-22
US29309110P 2010-01-07 2010-01-07
US61/293,091 2010-01-07
PCT/DK2010/000183 WO2011076208A2 (en) 2009-12-22 2010-12-22 Calcipotriol monohydrate nanocrystals

Publications (1)

Publication Number Publication Date
CA2785253A1 true CA2785253A1 (en) 2011-06-30

Family

ID=43618145

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2785253A Abandoned CA2785253A1 (en) 2009-12-22 2010-12-22 Calcipotriol monohydrate nanocrystals

Country Status (15)

Country Link
US (2) US20130039952A1 (cg-RX-API-DMAC7.html)
EP (1) EP2515874B1 (cg-RX-API-DMAC7.html)
JP (1) JP5816194B2 (cg-RX-API-DMAC7.html)
CN (1) CN102770125B (cg-RX-API-DMAC7.html)
AU (1) AU2010335655B2 (cg-RX-API-DMAC7.html)
BR (1) BR112012015449B1 (cg-RX-API-DMAC7.html)
CA (1) CA2785253A1 (cg-RX-API-DMAC7.html)
ES (1) ES2523119T3 (cg-RX-API-DMAC7.html)
IL (1) IL220516A (cg-RX-API-DMAC7.html)
MX (1) MX2012007234A (cg-RX-API-DMAC7.html)
NZ (1) NZ601000A (cg-RX-API-DMAC7.html)
PL (1) PL2515874T3 (cg-RX-API-DMAC7.html)
RU (1) RU2555339C2 (cg-RX-API-DMAC7.html)
WO (1) WO2011076208A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA201204618B (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR122019026637B1 (pt) * 2013-07-18 2023-09-26 Mannkind Corporation Formulações farmacêuticas de pó seco e método para a fabricação de uma formulação de pó seco
CN105534996B (zh) * 2016-02-24 2018-05-01 长沙佰顺生物科技有限公司 一种治疗银屑病的药物组合物
KR20190042558A (ko) 2016-07-05 2019-04-24 크라토스 엘엘씨 부동태화된 예비리튬화된 마이크론 및 서브마이크론 iva족 입자 및 이의 제조방법
US11637280B2 (en) 2017-03-31 2023-04-25 Kratos LLC Precharged negative electrode material for secondary battery
CN108904445A (zh) * 2018-08-06 2018-11-30 江苏知原药业有限公司 钙泊三醇纳米悬浮液
CN109157661B (zh) * 2018-09-10 2021-09-24 南京工业大学 一种配体辅助下用氧化物silica包覆疏水性分子晶体的方法
RU2749360C1 (ru) * 2020-10-09 2021-06-09 Федеральное государственное бюджетное военное образовательное учреждение высшего образования "Военно-медицинская академия имени С.М. Кирова" Министерства обороны Российской Федерации (ВМедА) Способ лечения ладонно-подошвенного пустулеза
JP7751298B2 (ja) * 2021-07-14 2025-10-08 株式会社ツツミプランニング 浸透深さの調整方法

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8315787D0 (en) * 1983-06-08 1983-07-13 Briggs J H Coolant spray
US4758432A (en) * 1984-10-15 1988-07-19 Richardson-Vicks Inc. Topical treatment of skin inflammatory disorders
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
USRE39706E1 (en) * 1993-01-15 2007-06-26 Leo Pharma A/S Crystalline form of a vitamin D analogue
DE4440337A1 (de) * 1994-11-11 1996-05-15 Dds Drug Delivery Services Ges Pharmazeutische Nanosuspensionen zur Arzneistoffapplikation als Systeme mit erhöhter Sättigungslöslichkeit und Lösungsgeschwindigkeit
GB9504265D0 (en) * 1995-03-03 1995-04-19 Medeva Plc Corticosteroid-containing pharmaceutical composition
US8263580B2 (en) * 1998-09-11 2012-09-11 Stiefel Research Australia Pty Ltd Vitamin formulation
DE19932157A1 (de) 1999-07-13 2001-01-18 Pharmasol Gmbh Verfahren zur schonenden Herstellung von hochfeinen Mikropartikeln und Nanopartikeln
US6403654B1 (en) * 2000-04-13 2002-06-11 Mariana De Oliveira Compositions for and method of treatment for psoriasis
WO2002034235A1 (en) * 2000-10-27 2002-05-02 Leo Pharma A/S Topical composition containing at least one vitamin d or one vitamin d analogue and at least one corticosteroid
WO2002045691A2 (en) * 2000-12-06 2002-06-13 Pharmacia Corporation Laboratory scale milling process
FR2834212B1 (fr) * 2001-12-27 2004-07-09 Besins Int Belgique Utilisation d'une poudre a liberation immediate dans des compositions pharmaceutiques et nutraceutiques
AU2002356294A1 (en) 2002-12-13 2004-07-09 Jagotec Ag A topical nanoparticulate spironolactone formulation
RU2396250C2 (ru) 2003-07-24 2010-08-10 Лео Фарма А/С Новые производные аминобензофенона
JP2007536259A (ja) * 2004-05-06 2007-12-13 イヴレア ファーマスーティカルズ インコーポレイテッド 活性薬剤の送達のための粒子
US20060110415A1 (en) * 2004-11-22 2006-05-25 Bioderm Research Topical Delivery System for Cosmetic and Pharmaceutical Agents
EP1828148B1 (en) 2004-12-13 2010-01-20 Leo Pharma A/S Triazole substituted aminobenzophenone compounds
ES2447301T3 (es) * 2005-06-01 2014-03-11 Glaxosmithkline Intellectual Property Development Limited Formulación vitamínica
US20070154402A1 (en) * 2005-10-24 2007-07-05 Collegium Pharmaceutical, Inc. Topical Pharmaceutical Foam Composition
JP5508003B2 (ja) * 2006-06-30 2014-05-28 アイスイティカ ピーティーワイ リミテッド ナノ粒子状の形態における生物学的に活性な化合物の調製のための方法
WO2008058755A1 (en) * 2006-11-17 2008-05-22 Abbott Gmbh & Co. Kg Nanocrystals for use in topical cosmetic formulations and method of production thereof
US8148537B2 (en) 2006-12-22 2012-04-03 Leo Pharma A/S Substituted acetophenones useful as PDE4 inhibitors
PL2114951T3 (pl) 2007-02-28 2014-10-31 Leo Pharma As Nowe inhibitory fosfodiesterazy
CN101677979A (zh) 2007-04-19 2010-03-24 利奥制药有限公司 Src家族激酶抑制剂
JP2010526824A (ja) 2007-05-11 2010-08-05 ソネボーン インコーポレイテッド シリコーン類似の特性を有するワセリン
PL2379548T3 (pl) 2008-12-19 2016-08-31 Leo Pharma As Triazolopirydyny jako inhibitory fosfodiesterazy do leczenia chorób skórnych

Also Published As

Publication number Publication date
NZ601000A (en) 2014-07-25
JP5816194B2 (ja) 2015-11-18
ES2523119T3 (es) 2014-11-21
IL220516A (en) 2015-06-30
HK1177694A1 (en) 2013-08-30
CN102770125B (zh) 2015-02-11
CN102770125A (zh) 2012-11-07
ZA201204618B (en) 2013-09-25
EP2515874A2 (en) 2012-10-31
WO2011076208A2 (en) 2011-06-30
BR112012015449A2 (pt) 2016-03-15
MX2012007234A (es) 2012-07-30
WO2011076208A3 (en) 2012-03-01
US20130039952A1 (en) 2013-02-14
BR112012015449B1 (pt) 2021-09-28
RU2555339C2 (ru) 2015-07-10
AU2010335655A1 (en) 2012-07-19
JP2013515019A (ja) 2013-05-02
PL2515874T3 (pl) 2015-01-30
RU2012130412A (ru) 2014-01-27
US20140322331A1 (en) 2014-10-30
EP2515874B1 (en) 2014-08-20
AU2010335655B2 (en) 2015-03-05

Similar Documents

Publication Publication Date Title
US20140322331A1 (en) Calcipotriol monohydrate nanocrystals
EP2515865B1 (en) Cutaneous composition comprising vitamin d analogue and a mixture of solvent and surfactants
AU2009357263B2 (en) Pharmaceutical composition comprising vitamin D analogue and cosolvent-surfactant mixture
EP2515866B1 (en) Pharmaceutical composition comprising solvent mixture and a vitamin d derivative or analogue
US9254296B2 (en) Pharmaceutical composition comprising vitamin D analogue and cosolvent-surfactant mixture
CN108904445A (zh) 钙泊三醇纳米悬浮液
HK1177694B (en) Calcipotriol monohydrate nanocrystals
HK1177696B (en) Pharmaceutical composition comprising solvent mixture and a vitamin d derivative or analogue

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20151207

FZDE Discontinued

Effective date: 20181003